BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

CAPS Rating: 1 out of 5

A biotechnology company, which designs, optimizes and develops novel drugs that block key enzymes involved in cancer, cardiovascular diseases, autoimmune diseases, and viral infections.

Results 1 - 20 of 38 : 1 2 Next »

Recs

0
Member Avatar TerryFool (20.72) Submitted: 4/15/2014 11:55:35 AM : Outperform Start Price: $7.92 BCRX Score: +60.25

buy now target price 12

Recs

0
Member Avatar TerryHoodSr (60.36) Submitted: 4/15/2014 10:18:42 AM : Outperform Start Price: $8.10 BCRX Score: +56.90

trade buy@ 8.4 TP 13

Recs

0
Member Avatar davidhorn1 (< 20) Submitted: 8/23/2013 10:09:47 AM : Outperform Start Price: $5.95 BCRX Score: +106.06

Because new innovations, it was underated.

Recs

0
Member Avatar NoDoughBro (70.63) Submitted: 7/23/2013 11:04:17 PM : Outperform Start Price: $4.46 BCRX Score: +184.48

What the What what?!

Recs

0
Member Avatar karlsmq (< 20) Submitted: 7/19/2013 4:08:49 PM : Outperform Start Price: $2.83 BCRX Score: +358.56

excellent pipeline of drugs

Recs

0
Member Avatar Sytes (< 20) Submitted: 5/28/2013 11:30:37 PM : Outperform Start Price: $1.60 BCRX Score: +722.42

Will float to $4+ within next 2 yrs.

Recs

2
Member Avatar zzlangerhans (99.78) Submitted: 4/1/2013 11:44:35 AM : Underperform Start Price: $1.51 BCRX Score: -765.72

As I predicted, BioCryst still had a little life left which allowed me to escape my green thumb and flip turn into a red one. 33% jump today, and all because of this:

BioCryst Pharmaceuticals, Inc. today announced that it received a preliminary comment letter from the U.S. Food & Drug Administration (FDA) that outlines a pathway by which BioCryst could file a New Drug Application (NDA) seeking regulatory approval of intravenous (i.v.) peramivir.

That's just about the weakest endorsement I've ever heard. The FDA sees how BioCryst can actually file an NDA for peramivir, despite the drug having failed in pivotal trials. That of course does not describe a path towards FDA approval or even NDA acceptance, just NDA filing. All this development means is that BioCryst will expend more resources in a fruitless quest for approval of peramivir. Meanwhile, BARDA has simultaneously instructed the company to stop work on the DoD peramivir project. Doesn't sound like the same government is salivating to improve this drug.

Recs

0
Member Avatar EvilEmpire (29.54) Submitted: 5/12/2012 9:54:26 AM : Outperform Start Price: $3.66 BCRX Score: +219.41

BB

Recs

0
Member Avatar maphere (< 20) Submitted: 3/7/2012 4:22:47 PM : Outperform Start Price: $5.62 BCRX Score: +93.19

Multiple drug candidates for partnerships (gout and Hep C)

Antiviral IV Peramivir for govt. stockpiling and future commercialization. There are no IV antivirals for hospitalized patients.

Recs

0
Member Avatar hollyalley11 (46.38) Submitted: 8/9/2010 4:16:01 PM : Outperform Start Price: $5.50 BCRX Score: +66.30

Struggled the past year. Will correct.

Recs

0
Member Avatar hammers23 (< 20) Submitted: 4/14/2010 9:31:07 AM : Outperform Start Price: $8.04 BCRX Score: +1.00

a product that's been proven 90% successful in worst case flu situations, EUA with full approval within 12 months maybe sooner, stockpiling orders lined up, 3 years of cash on books, strong potential gout drug in pipline...what's not to like...

Recs

0
Member Avatar zaktaylor33 (< 20) Submitted: 11/13/2009 1:23:32 PM : Outperform Start Price: $12.24 BCRX Score: -72.28

following tmf on this one

Recs

0
Member Avatar jeffsedlak (< 20) Submitted: 11/10/2009 5:16:08 PM : Outperform Start Price: $11.92 BCRX Score: -68.70

The "Emergency Use Authorization" Bcrx is pushing the stock in the short term. Production of their life saving IV drug "Peramivir" is currently limited. The final authorization to use the anti viral drug will coincide with the ramping up of production capacity, all to give this stock a steady upwards rise for many quarters.

Recs

0
Member Avatar billmilosh (< 20) Submitted: 11/2/2009 10:49:24 PM : Outperform Start Price: $9.94 BCRX Score: -57.66

If flue turns really bad, these guys have an IV solution. Working hard for international sales.

Recs

0
Member Avatar RoachFool (31.55) Submitted: 9/8/2009 5:35:27 PM : Outperform Start Price: $10.50 BCRX Score: -66.99

From the president's council recs “HHS is moving forward with the purchase of intravenous antivirals for use under EUA for individuals who may require them.” $2.7B has been identified for anti-virals and vaccines; peramivir will be stockpiled, and an EUA will be coming shortly. If this doesn't happen, the stock will tank and many more people will die from H1N1 than should have.

Recs

0
Member Avatar jtimes2 (46.89) Submitted: 8/19/2009 3:41:54 PM : Outperform Start Price: $9.98 BCRX Score: -66.89

N1H1 Viris Drug

Recs

0
Member Avatar clawmann (< 20) Submitted: 8/12/2009 6:58:10 AM : Outperform Start Price: $9.21 BCRX Score: -55.98

Expect FDA approval of its anti-viral and substantial orders thereafter.

Recs

1
Member Avatar asdadasdasasasas (34.31) Submitted: 6/6/2009 11:32:36 AM : Outperform Start Price: $4.17 BCRX Score: +107.63

Speculative play based on bullish sentiment from Michael Murphy; big potential if Emergency Use Authorization is granted in the next few weeks.

Recs

0
Member Avatar PhillyDan (79.46) Submitted: 5/27/2009 2:11:52 PM : Outperform Start Price: $4.70 BCRX Score: +62.88

Swine Flu vaccine, need I say more...

Recs

0
Member Avatar clutedog (65.34) Submitted: 4/30/2009 2:21:37 PM : Underperform Start Price: $3.88 BCRX Score: -117.22

Swine flu? Are you kidding me? This will blow over and these companies will have produced enough product for billions of people who are all perfectly healthy. Thanks, 24-hour news cycle, for making a mountain out of a molehill...

Results 1 - 20 of 38 : 1 2 Next »

Featured Broker Partners


Advertisement